Q2 revenue falls 3%, but profit rises 2%; solar project approved
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty Midcap 150 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the quarter ended 30 September 2025, consolidated revenue was Rs 97,994 lakh, down 3% year on year, while profit rose 2% to Rs 25,749 lakh. Half-year revenue fell 2% to Rs 178,511 lakh, but profit rose 6% to Rs 46,250 lakh. Profit included a Rs 264 lakh one-time property sale gain. The board also approved Rs 1.74 crore for a 26% stake in a 4.95 MWp solar project.
Lower revenue and higher profit indicate mixed performance. The small renewable energy investment may help reduce energy costs over time.